InteRNA is a biotech firm based in the Netherlands that specializes in developing RNA therapeutics for the treatment of cancer. Through its leading microRNA (miRNA) discovery and functional validation platform, InteRNA is working on a series of exclusive preclinical miRNA drug candidates that target critical processes in cancer initiation and progression. Equipped with a third-generation drug delivery formulation, these miRNA compounds have the capability to launch a synchronized anti-cancer offensive by simultaneously engaging multiple signal transduction targets. This approach aims to fulfill the urgent demand for innovative therapeutics with enhanced effectiveness.